These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 10617083)
61. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Plumb JA; Bilsland A; Kakani R; Zhao J; Glasspool RM; Knox RJ; Evans TR; Keith WN Oncogene; 2001 Nov; 20(53):7797-803. PubMed ID: 11753658 [TBL] [Abstract][Full Text] [Related]
62. Bystander cell killing spreading from endothelial to tumor cells in a three-dimensional multicellular nodule model after Escherichia coli nitroreductase gene delivery. Benouchan M; Do Nascimento F; Sebbah-Louriki M; Salzmann JL; Crépin M; Perret GY; Colombo BM Biochem Biophys Res Commun; 2003 Nov; 311(4):822-8. PubMed ID: 14623255 [TBL] [Abstract][Full Text] [Related]
63. Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture. Li Z; Han J; Jiang Y; Browne P; Knox RJ; Hu L Bioorg Med Chem; 2003 Sep; 11(19):4171-8. PubMed ID: 12951148 [TBL] [Abstract][Full Text] [Related]
64. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954. de Poorter JJ; Tolboom TC; Rabelink MJ; Pieterman E; Hoeben RC; Nelissen RG; Huizinga TW J Gene Med; 2005 Nov; 7(11):1421-8. PubMed ID: 15977303 [TBL] [Abstract][Full Text] [Related]
65. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Searle PF; Chen MJ; Hu L; Race PR; Lovering AL; Grove JI; Guise C; Jaberipour M; James ND; Mautner V; Young LS; Kerr DJ; Mountain A; White SA; Hyde EI Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):811-6. PubMed ID: 15566399 [TBL] [Abstract][Full Text] [Related]
75. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. Denny WA; Wilson WR J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483 [TBL] [Abstract][Full Text] [Related]
76. Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo. Harvey TJ; Hennig IM; Shnyder SD; Cooper PA; Ingram N; Hall GD; Selby PJ; Chester JD Cancer Gene Ther; 2011 Nov; 18(11):773-84. PubMed ID: 21836632 [TBL] [Abstract][Full Text] [Related]